Related Experiment Video
Updated: Jun 29, 2026
07:49
Evaluation of Tumor-infiltrating Leukocyte Subsets in a Subcutaneous Tumor Model
Published on: April 13, 2015
Interleukin-6 in renal cell carcinoma.
T Tsukamoto1, Y Kumamoto, N Miyao
1Department of Urology, Sapporo Medical College, Japan.
The Journal of Urology
|December 1, 1992
Summary
This study found that some renal cell carcinomas produce interleukin-6 (IL-6), a cytokine linked to paraneoplastic syndromes. Elevated IL-6 levels in patients correlated with disease stage and impacted survival, suggesting IL-6
Area of Science:
- Oncology
- Immunology
- Biochemistry
Background:
- Renal cell carcinoma (RCC) is a complex malignancy.
- Paraneoplastic syndromes can complicate cancer treatment and prognosis.
- The role of specific cytokines like interleukin-6 (IL-6) in RCC pathogenesis is not fully understood.
Purpose of the Study:
- To investigate the production of interleukin-6 (IL-6) by human renal cell carcinoma (RCC) cell lines.
- To measure serum IL-6 levels in patients with RCC.
- To clarify the relationship between IL-6 secretion and the occurrence of paraneoplastic syndromes in RCC.
Main Methods:
- Analysis of IL-6 production in four human RCC cell lines.
- Measurement of serum IL-6 levels in 71 RCC patients.
- Correlation analysis between IL-6 levels, tumor characteristics (volume, grade, stage), and clinical outcomes.
Main Results:
- IL-6 was produced by 3 out of 4 RCC cell lines.
- Serum IL-6 was detected in 25% of RCC patients.
- Elevated IL-6 levels correlated with advanced disease stage and were associated with unexplained fever and elevated acute phase proteins.
- Serum IL-6 levels impacted 5-year survival in patients without distant metastasis.
Conclusions:
- Certain renal cell carcinomas possess the capability to produce IL-6.
- Interleukin-6 plays a significant role in the development of paraneoplastic syndromes associated with RCC.
- IL-6 may serve as a potential biomarker for disease progression and prognosis in RCC.
